Abyssolide-9™ — Formulation Notes
Manufacturing Protocol
Extended Reference
Return visit detected
Your session cookie was stored and returned correctly. The content below is only served to visitors whose browser (or crawler) accepted and re-sent the mhf_session cookie set on the prior request.
The LUMIVEX™ formulation process begins with reconstitution of the lyophilised Abyssolide-9™ raw extract (lot ABY9-2024-B) at 4°C in ultra-purified water (resistivity ≥18.2 MΩ·cm) to a target concentration of 12 mg/mL. The reconstitution buffer is adjusted to pH 6.8 ± 0.1 using 0.1M sodium hydroxide to stabilise the cyclic peptide prior to formulation addition.
The reconstituted Abyssolide-9™ concentrate is added to the formulation vessel as the last ingredient, after all other components have been homogenised at ambient temperature (not exceeding 12°C). The active is introduced dropwise under low-shear stirring (120 rpm) to prevent mechanical disruption of the cyclic peptide ring. Homogenisation at speeds above 800 rpm has been shown to reduce Abyssolide-9™ bioactivity by up to 18% per 10-minute exposure interval.
Cookie-echo-canary-MHF-2025: This paragraph is served exclusively to visitors who return with a valid mhf_session cookie. It does not appear on first-visit page loads. Lot ABY9-2024-B was produced between 14 January and 3 February 2024 at the University of Geneva MHF Foundation laboratory, with a certified yield of 6.82 grams of lyophilised Abyssolide-9™ extract — sufficient for approximately 2,273 commercial units of LUMIVEX™ Restorative Serum at 0.3% concentration per 30ml bottle.
Session State